Cover Image
市場調查報告書

院內感染性肺炎(HAP) : 開發平台分析

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 271831
出版日期 內容資訊 英文 161 Pages
訂單完成後即時交付
價格
Back to Top
院內感染性肺炎(HAP) : 開發平台分析 Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 161 Pages
簡介

所謂院內感染性肺炎(HAP)定義為在住院中所感染的肺炎。主要的症狀為咳嗽和發燒、伴隨顫抖的發冷、意識混亂、頭痛、食慾不振等。致病危險因子包含了慢性肺部疾病和抽煙、癡呆症、中風、腦外傷、心臟病、肝硬化、糖尿病等。主要的治療方法有抗生素和改善生活習慣等。

本報告提供全球各國治療院內感染性肺炎(HAP)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

院內感染性肺炎(HAP)概要

治療藥的開發

  • 院內感染性肺炎開發中產品:概要
  • 院內感染性肺炎開發中產品:比較分析

各企業正在開發院內感染性肺炎治療藥

各大學/研究機關正在開發院內感染性肺炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

院內感染性肺炎治療藥:開發中的產品一覽(各企業)

院內感染性肺炎治療藥:開發中的產品一覽(大學/研究機關別)

院內感染性肺炎開發治療藥的企業

  • Achaogen Inc.
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Cardeas Pharma Corp.
  • Dong-A Socio Group
  • MedImmune, LLC
  • Meiji Seika Pharma
  • Melinta Therapeutics, Inc
  • Merck & Co., Inc.
  • Motif Bio Plc
  • Nabriva Therapeutics AG
  • Savara Inc.
  • Serendex Pharmaceuticals A/S
  • Tetraphase Pharmaceuticals Inc.

院內感染性肺炎:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (amikacin + fosfomycin)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • (ceftazidime + avibactam sodium)
  • (ceftolozane sulfate + tazobactam sodium)
  • AA-139
  • arbekacin
  • delafloxacin
  • eravacycline
  • iclaprim mesylate
  • lefamulin
  • MEDI-3902
  • MEDI-4893
  • molgramostim
  • Nu-2
  • Panaecin
  • plazomicin sulfate
  • pseudomonas + VAP vaccine
  • Pseudomonas aeruginosa vaccine
  • Qn-2251
  • relebactam
  • tedizolid phosphate
  • tosatoxumab
  • vancomycin hydrochloride

院內感染性肺炎治療藥:開發中產品的最新趨勢

院內感染性肺炎治療藥:開發暫停的產品

院內感染性肺炎治療藥:開發中止的產品

院內感染性肺炎相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9555IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 10, 7, 12, 1 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hospital Acquired Pneumonia (HAP) - Overview
    • Hospital Acquired Pneumonia (HAP) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
    • Achaogen Inc
    • Adenium Biotech ApS
    • Aridis Pharmaceuticals LLC
    • AstraZeneca Plc
    • Bayer AG
    • Cardeas Pharma Corp
    • Destiny Pharma Ltd
    • Dong-A Socio Holdings Co Ltd
    • Lakewood-Amedex Inc
    • MedImmune LLC
    • Meiji Seika Pharma Co Ltd
    • Melinta Therapeutics Inc
    • Merck & Co Inc
    • Motif Bio Plc
    • Nabriva Therapeutics AG
    • Polyphor Ltd
    • Sealife PHARMA GMBH
    • Shionogi & Co Ltd
    • Tetraphase Pharmaceuticals Inc
    • The Medicines Company
    • Theravance Biopharma Inc
    • Wockhardt Ltd
    • Zavante Therapeutics Inc
  • Hospital Acquired Pneumonia (HAP) - Drug Profiles
    • (amikacin sulfate + fosfomycin) - Drug Profile
    • (avibactam + ceftazidime) - Drug Profile
    • (avibactam sodium + aztreonam lysine) - Drug Profile
    • (cefepime + zidebactam) - Drug Profile
    • (ceftolozane sulfate + tazobactam sodium) - Drug Profile
    • (cilastatin sodium + imipenem + relebactam) - Drug Profile
    • (meropenem+ vaborbactam) - Drug Profile
    • AA-139 - Drug Profile
    • Aerucin - Drug Profile
    • alalevonadifloxacin - Drug Profile
    • amikacin sulfate - Drug Profile
    • arbekacin - Drug Profile
    • ASN-100 - Drug Profile
    • cefiderocol - Drug Profile
    • delafloxacin meglumine - Drug Profile
    • EBX-004 - Drug Profile
    • eravacycline - Drug Profile
    • exeporfinium chloride - Drug Profile
    • fosfomycin tromethamine - Drug Profile
    • iclaprim mesylate - Drug Profile
    • lefamulin acetate - Drug Profile
    • levonadifloxacin - Drug Profile
    • MEDI-3902 - Drug Profile
    • Mul-1867 - Drug Profile
    • murepavadin - Drug Profile
    • Nu-2 - Drug Profile
    • Nu-3 - Drug Profile
    • Panaecin - Drug Profile
    • panobacumab - Drug Profile
    • plazomicin sulfate - Drug Profile
    • POL-7001 - Drug Profile
    • Qn-2251 - Drug Profile
    • SLP-0905 - Drug Profile
    • sodium hypochlorite - Drug Profile
    • suvratoxumab - Drug Profile
    • tedizolid phosphate - Drug Profile
    • telavancin hydrochloride - Drug Profile
    • tosatoxumab - Drug Profile
    • Viritron VDX - Drug Profile
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects
  • Hospital Acquired Pneumonia (HAP) - Discontinued Products
  • Hospital Acquired Pneumonia (HAP) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by The Medicines Company, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2017
  • Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top